Viral-based Vaccines, Antibody Directed Immuno-Conjugates
Total Trials
13
As Lead Sponsor
9
As Collaborator
4
Total Enrollment
373
NCT01491893
PVSRIPO for Recurrent Glioblastoma (GBM)
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 25, 2012
Completion: Oct 1, 2021
NCT02986178
Lerapolturev in Recurrent Malignant Glioma
Phase: Phase 2
Start: Jun 1, 2017
Completion: Feb 3, 2023
NCT03043391
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Start: Nov 7, 2017
Completion: Mar 23, 2022
NCT03712358
PVSRIPO for Patients With Unresectable Melanoma
Start: Nov 26, 2018
Completion: Mar 23, 2021
NCT03564782
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
Phase: Early Phase 1
Start: Jun 30, 2019
Completion: Apr 11, 2022
NCT04160494
D2C7-IT With Atezolizumab for Recurrent Gliomas
Role: Collaborator
Start: Feb 25, 2020
Completion: Dec 31, 2027
NCT03973879
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Phase: Phase 1/2
Start: Feb 29, 2020
Completion: Jan 31, 2024
NCT04125719
PVSRIPO in Combination With Nivolumab in Melanoma
Start: Jun 1, 2020
Completion: Oct 1, 2024
NCT04479241
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Start: Oct 21, 2020
Completion: Jun 21, 2024
NCT04577807
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Start: Nov 17, 2020
Completion: Nov 15, 2024
NCT04690699
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Start: Aug 1, 2021
Completion: Jun 12, 2024
NCT06177964
Lerapolturev (PVSRIPO) in GBM
Start: Jul 15, 2024
Completion: Feb 28, 2029
Loading map...